The OP quoted:
"His reasoning was based on two things: (1) if I add ADT we wouldn't know if the SRT worked until the ADT was out of the system and (2) there are no studies that show ADT providing a benefit in the SRT case, only in the case before surgery where radiation is the primary treatment."With all due respect, I think the second statement is only partially correct. There is evidence that ADT adjuvant to SRT delays biological recurrence, but it is retrospective evidence, not a randomized clinical trial. However the magnitude of the effect is quite significant: the difference between ADT and no ADT is actually greater than the difference between lymph node positive and lymph node negative!
Read here:
nomograms.mskcc.org/Prostate/SalvageRadiationTherapy.aspx...and read the back up reasearch here: Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007 May 20;25(15):2035-41. Erratum in: J Clin Oncol. 2007 Sep 10;25(26):4153.
The key quote from the abstract is here: "Significant variables in the model were PSA level before SRT (P < .001), prostatectomy Gleason grade (P < .001), PSA doubling time (P < .001), surgical margins (P < .001),
androgen-deprivation therapy before or during SRT (P < .001), and lymph node metastasis (P = .019). " Read it here:
www.ncbi.nlm.nih.gov/pubmed/17513807?dopt=Citation The full text is free; you can download the pdf and read the entire study.
This research was done by noted PC experts Stephenson, Scardino, Kattan and others at the Cleveland Clinic. Published in the Journal of Clinical Oncology.
Post Edited (proscapt) : 1/16/2013 11:29:09 PM (GMT-7)